RxGen to Deliver Multiple Presentations at Association for Research in Vision and Ophthalmology Annual Meeting
NEW HAVEN, Conn., April 22, 2019 (GLOBE NEWSWIRE) -- RxGen, a preclinical translational research company, today announced that the company will be presenting at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO) in Vancouver, Canada from April 28 to May 2, 2019. RxGen will present five posters describing the development of new disease models and methods of efficacy characterization for multiple ophthalmologic indications for which standard translational modeling has been inadequately predictive. Presentation details are below:
Poster presentation details
Presentation Title: Multiphoton microscopy for three-dimensional histology of retinal whole mounts Session: Session 109 - Animal Imaging Number: A0592 Date/Time: Sunday, April 28 from 8:00 am – 9:45 am PDT Presentation Title: Quantification of fluorescein leakage induced by DL-2-aminoadipic acid in an experimental model of chronic neovascular leakage Session: Session 109 - Animal Imaging Number: A0609 Date/Time: Sunday, April 28 from 8:00 am – 9:45 am PDT Presentation Title: Optimization of trabecular meshwork laser strategy to achieve sustained 2-3X intraocular pressure elevation and glaucomatous optic neuropathy in primates Session: Session 137 - Neuroprotection Number: B0123 Date/Time: Sunday, April 28 from 1:00 pm – 2:45 pm PDT Presentation Title: Circadian rhythm mediated regulation of the inner blood retina barrier; Relevance for geographic atrophy development Session: Session 328 - AMD Translational Studies Number: A0280 Date/Time: Tuesday, April 30 from 8:45 am – 10:30 am PDT Presentation Title: Characterization of DL-2-aminoadipic acid-induced histopathological changes in nonhuman primate retina Session: Session 515 - Retinal Cell Biology Number: A0490 Date/Time: Thursday, May 2 from 8:00 am – 9:45 am PDT Presentation Title: Application of a nonhuman primate model of retinal detachment to evaluate neuroprotection efficacy Session: Session 545 - Retinal Detachment, Trauma and Repair Number: A0311 Date/Time: Thursday, May 2 from 10:15 am – 12:00 pm PDT
About RxGen (www.rx-gen.com) RxGen is a translational research company devoted to developing and providing predictive preclinical research models to accelerate therapeutic candidate development and reduce the risk of clinical failure. RxGen engages with leading pharmaceutical, biotechnology and academic sponsors and collaborators to design and execute a wide range of preclinical studies and translational research programs across various therapeutic areas. Application of RxGen’s unique translational capabilities is enabled by flexible scientific and commercial interactions that span contract research services, research collaborations and R&D partnering agreements.
RxGen: Christopher Stanley, Chief Business Officer RxGen 1 (203) 498-9796 email@example.com
Media: Michael Tattory, Account Executive LifeSci Public Relations1 (646) 751-4362 firstname.lastname@example.org